Mice lacking α-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration

被引:93
作者
Drolet, RE
Behrouz, B
Lookingland, KJ
Goudreau, JL [1 ]
机构
[1] Michigan State Univ, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA
[2] Michigan State Univ, Dept Neurol, E Lansing, MI 48824 USA
[3] Michigan State Univ, Neurosci Program, E Lansing, MI 48824 USA
关键词
Parkinson's disease; MPTP; alpha-synuclein; dopamine;
D O I
10.1016/j.neuro.2004.05.002
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The functional role of a-synuclein in the pathogenesis of Parkinson's disease (PD) is not fully understood. Systemic exposure of alpha-synuclein-deficient mice to neurotoxins provides a direct approach to evaluate how alpha-synuclein may mediate cell death in a common marine model of PD. To this end, wild-type and homozygous alpha-synuclein knock-out mice were treated with sub-chronic and prolonged, chronic exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In the sub-chronic model, wild-type and a-synuclein knock-out mice were treated for five consecutive days with MPTP (1-25 mg/kg, s.c.) or vehicle, and sacrificed 3 days,following the last injection. The prolonged, chronic model consisted of two injections of MPTP (1-20 mg/kg, s.c.) per week for 5 weeks, with co-administration of probenecid (250 mg/kg, i.p.), and animals were sacrificed 3 weeks following the last injection. Sub-chronic administration of MPTP caused a dramatic, dose-dependent decrease in striatal dopamine (DA) concentrations, while an attenuated response was observed in a-synuclein knock-out mice. Similarly, prolonged, chronic administration of MPTP produced a dose-dependent decrease in striatal DA concentrations, and a corresponding loss of striatal vesicular monoamine transporter (VMAT-2) protein in wild-type mice. However mice lacking alpha-synuclein had an attenuated loss of striatal DA concentrations, while no loss of striatal VMAT-2 protein was observed. Both sub-chronic and prolonged, chronic administration of MPTP caused an increase in the 3,4-dihydroxyphenylacetic acid (DOPAC) to DA ratio in wild-type mice, but not in mice lacking a-synuclein. Despite attenuated toxicity, elevated lactate concentrations were observed in alpha-synuclein knock-out mice following prolonged, chronic MPTP administration. The results of this study provide evidence that alpha-synuclein null mice have an attenuated response to the toxic effects of MPTP exposure, even over prolonged periods of time and that the biochemical sequela of a protracted insult to nigrostriatal DA neurons are distinct between mice with and without alpha-synuclein expression. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:761 / 769
页数:9
相关论文
共 39 条
[31]   L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice [J].
Reveron, ME ;
Savelieva, KV ;
Tillerson, JL ;
McCormack, AL ;
Di Monte, DA ;
Miller, GW .
NEUROTOXICOLOGY, 2002, 23 (4-5) :611-619
[32]   Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine-induced parkinsonism in mice [J].
Schlüter, OM ;
Fornai, F ;
Alessandri, MG ;
Takamori, S ;
Geppert, M ;
Jahn, R ;
Südhof, TC .
NEUROSCIENCE, 2003, 118 (04) :985-1002
[33]   α-synuclein locus triplication causes Parkinson's disease [J].
Singleton, AB ;
Farrer, M ;
Johnson, J ;
Singleton, A ;
Hague, S ;
Kachergus, J ;
Hulihan, M ;
Peuralinna, T ;
Dutra, A ;
Nussbaum, R ;
Lincoln, S ;
Crawley, A ;
Hanson, M ;
Maraganore, D ;
Adler, C ;
Cookson, MR ;
Muenter, M ;
Baptista, M ;
Miller, D ;
Blancato, J ;
Hardy, J ;
Gwinn-Hardy, K .
SCIENCE, 2003, 302 (5646) :841-841
[34]   Strain-dependent susceptibility to MPTP and MPP+-induced parkinsonism is determined by glia [J].
Smeyne, M ;
Goloubeva, O ;
Smeyne, RJ .
GLIA, 2001, 34 (02) :73-80
[35]   alpha-synuclein in Lewy bodies [J].
Spillantini, MG ;
Schmidt, ML ;
Lee, VMY ;
Trojanowski, JQ ;
Jakes, R ;
Goedert, M .
NATURE, 1997, 388 (6645) :839-840
[36]   In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining [J].
Tatton, NA ;
Kish, SJ .
NEUROSCIENCE, 1997, 77 (04) :1037-1048
[37]  
WESTERINK BHC, 1982, BRAIN RES, V252, P239, DOI 10.1016/0006-8993(82)90391-2
[38]   Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease [J].
Wilson, JM ;
Levey, AI ;
Rajput, A ;
Ang, L ;
Guttman, M ;
Shannak, K ;
Niznik, HB ;
Hornykiewicz, O ;
Pifl, C ;
Kish, SJ .
NEUROLOGY, 1996, 47 (03) :718-726
[39]  
Wilson JM, 1996, J NEUROSCI, V16, P3507